Hyperion Pricing On Ravicti Will Test Premium For Convenience In Orphan Market
This article was originally published in The Pink Sheet Daily
Ravicti’s price tag is $250,000 to $290,000 per year while the upper WAC price for Valeant’s competing product Buphenyl is roughly $240,000 at the maximum dose; Hyperion has option to acquire Buphenyl.
You may also be interested in...
The biotech revealed that its recently closed acquisition was conducted under false pretenses and that Andromeda employees had been manipulating clinical trial data for the late-stage type 1 diabetes drug.
In addition to the mega-deal, Valeant’s latest acquisition gambit and the Pfizer/AstraZeneca rumors, the hectic week saw Celgene pay a huge upfront for a Phase III Crohn’s candidate, Aastrom purchase Sanofi’s regenerative medicine business and The Medicines Company add to its surgical products portfolio.
The California biotech is adding to its orphan drug roster with the purchase of the Israeli biotech and its late-stage type 1 diabetes treatment in a back-loaded deal that leaves little room for risk.